ACT 335827 NEW
| Price | $1650 | $6670 |
| Package | 10mg | 50mg |
| Supply Ability: | 10g |
| Update Time: | 2026-04-22 |
Product Details
| Product Name: ACT 335827 | CAS No.: 1354039-86-3 |
| Supply Ability: 10g | Release date: 2026/04/22 |
Product Introduction
Bioactivity
| Name | ACT 335827 |
| Description | ACT-335827 is an orally available, brain-penetrant, orexin type 1 receptor-selective antagonist, with IC50 values of 6 nM for OXR1 and 417 nM for OXR2. It is suitable for studies related to neurological disorders [1]. |
| In vitro | ACT-335827 (0-10 μM, 2 h) demonstrates activity on OXR-1 (Kb = 41 nM, IC50 = 120 nM) and OXR-2 (Kb = 560 nM, IC50 = 2300 nM) in CHO cells [1]. |
| In vivo | ACT-335827 administered through oral gavage at doses ranging from 30-100 mg/kg once, effectively reduces the fear-induced startle response in rats, without impacting their motor or cognitive functions [1]. In contrast, continuous oral administration of ACT-335827 at a dose of 300 mg/kg daily for four weeks shows diminished effects on metabolic syndrome (MetS) symptoms, such as diet-induced obesity (DIO), in male Wistar rats [2]. Notably, the compound at 300 mg/kg reduces the preferential selection for high fat/sweet diets, increases water intake, and elevates HDL levels relative to total cholesterol, all while only resulting in a modest 4% weight gain compared with control subjects. Furthermore, it's reported that a 300 mg/kg dosage can diminish stress-induced elevations in body temperature and accelerate heart rate at both the 100 and 300 mg/kg doses, with no observable effects on locomotion and blood pressure. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | ACT-335827 | ACT335827 | ACT 335827 |
| Inhibitors Related | Tebideutorexant | Daridorexant hydrochloride | SB-334867 free base | YNT-185 | SB-408124 | Filorexant | Suntinorexton | OXA (17-33) acetate | SB-674042 | PF3274167 | ACT-462206 | Seltorexant |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $115.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-04-20 | |
| $98.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
| $1.10 |
VIP6Y
|
Dideu Industries Group Limited
|
2025-11-18 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY